|Fastest Growing Market:||Asia Pacific|
|Largest Market:||North America|
Need a report that reflects how COVID-19 has impacted this market and its growth?
The apheresis market was valued at approximately USD 1,639 million in 2020, and it is expected to witness a revenue of USD 2580 million in 2026, with a CAGR of 7.85% over the forecast period, 2021-2026.
The apheresis market is expected to be positively impacted during the COVID-19 pandemic owing to the extensive application of plasma therapy in the treatment of COVID-19 infected patients. Furthermore, in August 2020, the US FDA granted emergency use authorization (EUA) of convalescent plasma (CCP) therapy in hospitalized individuals with COVID-19. Also, in April 2020, Terumo BCT Inc. and Marker Therapeutics AG received the FDA approval for the Emergency Use Authorization (EUA) of Terumo BCT’s Spectra Optia Apheresis System combined with Marker Therapeutics’ D2000 Adsorption Cartridge to treat patients aged 18 years or above with confirmed COVID-19 disease. Thus, given the wide usage of apheresis units in the treatment of COVID-19 patients and increasing product approvals by the FDA, the apheresis market enjoys a positive growth over the pandemic.
The propelling factors for the growth of the apheresis market include the increasing number of diseases, a rise in the demand for blood components and associated safety, technological advancement in the development of new apheresis techniques, and a rise in the reimbursement policies and funding for apheresis procedures.
The use of apheresis in clinically ill patients is increasing day by day, and it has been widely used as the primary therapy or as an adjunct to other treatments for various diseases, such as thrombotic thrombocytopenic purpura, hemolytic uremic syndrome, drug toxicities, autoimmune disease, sepsis, and fulminant hepatic failure.
Additionally, as per the Centers for Disease Control and Prevention (CDC) 2019 report, it is estimated that about 37 million (15%) adults in the United States had chronic kidney disease (CKD). Apheresis plays a vital role in the purification of blood in patients with kidney disorders and drives the studied market. Along with these factors, the increasing product innovations and approvals have been driving the market growth. For instance, in June 2020, Fresenius Kabi AG and Fresenius Kabi USA received FDA clearance for ALYX Component Collection System, which is intended for use in blood collection establishments to collect and separate whole blood into its components. Thus, owing to the aforementioned factors, the apheresis market is expected to witness healthy growth over the forecast period.
Scope of the Report
As per the scope of the report, apheresis is a medical technique where the blood of an individual, be a donor or a patient, is passed through an apparatus that segregates out a particular constituent and returns the rest to the blood circulation. It involves blood purification and blood component separation by using centrifugation or membrane filtration technology. This procedure is performed for the blood donation component or for the treatment of disease. The apheresis market is segmented by product (devices and disposables), apheresis procedure (leukapheresis, plasmapheresis, plateletpheresis, erythrocytapheresis, and other apheresis procedures), technology (centrifugation and membrane separation), application (renal disorders, hematological disorders, neurological disorders, autoimmune disorders, and other applications), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.
|By Apheresis Procedure|
|Other Apheresis Procedures|
Key Market Trends
The Hematological Disorders Segment is Expected to Grow the Fastest during the Forecast Period
Hematological disorders make a substantial contribution to the morbidity and mortality of individuals across the globe. According to the World Federation of Hemophilia report 2019, the number of people identified with hemophilia increased from 78,629 in 1999 to 324,648 in 2019 globally. Furthermore, about 157,517 people across the world are suffering from hemophilia A, and about 31,997 people are suffering from hemophilia B. Hence, owing to the increasing burden of hematological incidences and growing applications of apheresis as a treatment method for hematological disorders, the apheresis market for hematological disorders is expected to experience growth in the forecast period. The recent years brought about a rise in new options of therapeutic aphereses, such as immunoadsorption, double filtration, and cytapheresis used in the treatment of both primary and secondary autoimmune renal diseases. Additionally, as per ClinicalTrails.gov, as of January 21, 2021, there are about 47 ongoing clinical trials related to apheresis for different hematological disease development across the United States.
According to the research article published in the Journal of Thrombosis and Thrombolysis, 2020, coagulation parameters such as D-dimer, platelet count, fibrinogen, prothrombin time (PT), or activated partial thromboplastin time (aPTT) were found to be often increased in severe COVID-19 cases with an increased risk of thromboembolic complications, and thus, can indirectly impact the studied segment during the pandemic.
Furthermore, apheresis plays a very crucial role in the management of sickle cell anemia disease. As per the study titled, “Role of Emergency Automated Red Cell Exchange in Sickle Cell Crisis: A Case Report”, published in November 2020, apheresis equipment was found to provide better management in red cell exchange therapeutic procedures being performed in sickle cell. Thus, owing to the aforementioned factors, the application of apheresis in treating various hematological disorders is expected to grow significantly over the forecast period.
To understand key trends, Download Sample Report
North America Holds the Major Share in the Studied Market and is Expected to Exhibit the Same Trend over the Forecast Period
The growing burden of various ailments related to blood such as kidney diseases, metabolic diseases, cancer, and neurological disorders, the presence of established healthcare infrastructure, and high patient awareness levels are the major factors driving the growth of the studied market in North America. According to the Leukemia & Lymphoma Society (LLS), approximately every three minutes, one person in the United States is being diagnosed with blood cancer. An estimated combined total of 178,520 people in the United States were expected to be diagnosed with leukemia, lymphoma, or myeloma in 2020. The new cases of leukemia, lymphoma, and myeloma accounted for 9.9% of the estimated 1,806,590 new cancer cases diagnosed in the United States in 2020. The high incidence of target diseases thus drives the studied market growth.
In May 2020, the Department of Defense in the United States began an effort to collect 8,000 donated units of plasma from patients who have recovered from COVID-19 to support the development of an effective treatment against the disease. This effort has given rise to the adoption of plasmapheresis devices and disposables in the United States.
Additionally, the increasing product approvals and presence of most of the major players in the region play a vital role in the growth of the studied market. For instance, in October 2020, Haemonetics Corporation received the FDA approval for its NexSys PCS system with Persona technology for plasma collection based on an individual donor's body composition. Thus, the aforementioned factors are associated with the significant growth of the apheresis market in North America over the forecast period.
To understand geography trends, Download Sample Report
The market studied is moderately competitive and is dominated by a few major players, and currently, the market is well established in many areas and has shown nascent success history. However, its full potential is yet to be determined in the developing regions. With increasing government initiatives, there is an awareness among people, which is further driving the growth of the market studied. Additionally, the strategic alliances and new product launches by the major companies are expected to drive the market growth. For instance, in January 2020, Fresenius Kabi invested EUR 30 million for the expansion of a transfusion and apheresis disposables plant in the Dominican Republic.
In December 2020, Marken announced the launch of two new facilities in Kyiv, Ukraine, and in Los Angeles, the United States, i.e., the Good Manufacturing Practice (GMP) depot and apheresis kit-building facility in Los Angeles (LA), to expand the company's ability to meet GMP storage and cell and gene supply chain services in the United States.
In August 2020, the Drugs Controller General of India (DGCI) gave its approval for using an apheresis machine to extract blood plasma in Goa for critically ill COVID-19 patients.
Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Global Disease Burden Resulting in Rise in Demand for Blood Components and Associated Safety
4.2.2 Technological Advancement in Development of New Apheresis Techniques
4.2.3 Rise in the Reimbursement Policies and Funding for Apheresis Procedures
4.3 Market Restraints
4.3.1 High Capital Investment and Costs Associated with Apheresis Procedures
4.3.2 Shortage of Skilled Professionals
4.3.3 Risk of Blood Contamination
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Product
5.2 By Apheresis Procedure
5.2.5 Other Apheresis Procedures
5.3 By Technology
5.3.2 Membrane Separation
5.4 By Application
5.4.1 Renal Disorders
5.4.2 Hematological Disorders
5.4.3 Neurological Disorders
5.4.4 Autoimmune Disorders
5.4.5 Other Applications
5.5.1 North America
220.127.116.11 United States
18.104.22.168 United Kingdom
22.214.171.124 Rest of Europe
126.96.36.199 South Korea
188.8.131.52 Rest of Asia-Pacific
5.5.4 Middle-East and Africa
184.108.40.206 South Africa
220.127.116.11 Rest of Middle-East & Africa
5.5.5 South America
18.104.22.168 Rest of South America
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.1 Asahi Kasei Corporation
6.1.2 B. Braun Melsungen AG
6.1.3 FRESENIUS SE & CO. KGAA (Fresenius Kabi AG)
6.1.4 Haemonetics Corporation
6.1.5 Terumo corporation (Terumo BCT)
6.1.6 Kaneka Corporation
6.1.7 Sumitomo Bakelite Company Limited (Kawasumi Laboratories Inc.)
6.1.8 Medica SPA
6.1.9 Baxter International
6.1.10 Cerus Corporation
6.1.11 Nikkiso Co. Ltd
6.1.12 Macopharma SA
6.1.13 Otsuka Holdings Co. Ltd
6.1.14 Mallinckrodt PLC
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Global Apheresis Market market is studied from 2018 - 2026.
What is the growth rate of Global Apheresis Market?
The Global Apheresis Market is growing at a CAGR of 7.85% over the next 5 years.
Which region has highest growth rate in Global Apheresis Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Global Apheresis Market?
North America holds highest share in 2020.
Who are the key players in Global Apheresis Market?
Fresenius SE & Co. KGaA, B. Braun Melsungen AG, Asahi Kasei Corporation, Haemonetics Corporation , Terumo Corporation (Terumo BCT) are the major companies operating in Global Apheresis Market.